Mirador closed a $250 million Series B with premier investors to advance its immuno-fibrotic disease pipeline.
- Amount
- $250M
- Stage
- Series B
- Announced
- 12 January 2026
- Investors
- T. Rowe Price Investment Management, Inc., Adage Capital Partners L.P., Fidelity Management & Research Company, ARCH Venture Partners, OrbiMed, Fairmount, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital
- Use of funds
- The proceeds enable Mirador to deliver proof-of-concept across all current programs and support the development of additional pipeline candidates.
- Total raised
- $650M to date
- Checked
- Amount and date checked against the press source